These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Saxagliptin (Onglyza) for type 2 diabetes. Med Lett Drugs Ther; 2009 Nov; 51(1324):85-6. PubMed ID: 19890244 [No Abstract] [Full Text] [Related]
3. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. Scheen AJ Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):383-94. PubMed ID: 22313172 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. Karyekar C; Donovan M; Allen E; Fleming D; Ravichandran S; Chen R Postgrad Med; 2011 Jul; 123(4):63-70. PubMed ID: 21680990 [TBL] [Abstract][Full Text] [Related]
5. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Rosenstock J; Sankoh S; List JF Diabetes Obes Metab; 2008 May; 10(5):376-86. PubMed ID: 18355324 [TBL] [Abstract][Full Text] [Related]
6. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Göke B; Gallwitz B; Eriksson J; Hellqvist A; Gause-Nilsson I; Int J Clin Pract; 2010 Nov; 64(12):1619-31. PubMed ID: 20846286 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Scheen AJ; Charpentier G; Ostgren CJ; Hellqvist A; Gause-Nilsson I Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678 [TBL] [Abstract][Full Text] [Related]
8. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. Rosenstock J; Mathieu C; Chen H; Garcia-Sanchez R; Saraiva GL Arch Endocrinol Metab; 2018 Aug; 62(4):424-430. PubMed ID: 30304106 [TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin. Del Prato S; Rosenstock J; Garcia-Sanchez R; Iqbal N; Hansen L; Johnsson E; Chen H; Mathieu C Diabetes Obes Metab; 2018 Jun; 20(6):1542-1546. PubMed ID: 29446523 [TBL] [Abstract][Full Text] [Related]
10. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Jadzinsky M; Pfützner A; Paz-Pacheco E; Xu Z; Allen E; Chen R; Diabetes Obes Metab; 2009 Jun; 11(6):611-22. PubMed ID: 19515181 [TBL] [Abstract][Full Text] [Related]
11. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898 [TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes. Med Lett Drugs Ther; 2018 Mar; 60(1543):55-56. PubMed ID: 29635266 [No Abstract] [Full Text] [Related]
13. The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial. Dore FJ; Domingues CC; Ahmadi N; Kundu N; Kropotova Y; Houston S; Rouphael C; Mammadova A; Witkin L; Khiyami A; Amdur RL; Sen S Cardiovasc Diabetol; 2018 May; 17(1):65. PubMed ID: 29724198 [TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943 [TBL] [Abstract][Full Text] [Related]
15. Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs. LaSalle JR Postgrad Med; 2010 Jan; 122(1):144-52. PubMed ID: 20107298 [TBL] [Abstract][Full Text] [Related]
17. No benefit of saxagliptin on cardiovascular outcomes in type 2 diabetes mellitus: potential explanations. Jialal I; Dhindsa S Metab Syndr Relat Disord; 2014 Apr; 12(3):157-8. PubMed ID: 24520851 [No Abstract] [Full Text] [Related]
18. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials. Cook W; Bryzinski B; Slater J; Frederich R; Allen E Postgrad Med; 2013 May; 125(3):145-54. PubMed ID: 23748515 [TBL] [Abstract][Full Text] [Related]
19. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Cook W; Minervini G; Bryzinski B; Hirshberg B Postgrad Med; 2014 Oct; 126(6):19-32. PubMed ID: 25414932 [TBL] [Abstract][Full Text] [Related]
20. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. Guarino E; Nigi L; Patti A; Fondelli C; Dotta F Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]